Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicotinate
Drug ID BADD_D01563
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Marketing Status Prescription; Discontinued
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 937
TTD Drug ID Not Available
NDC Product Code 59651-018; 65162-322; 71740-001; 65372-1194; 47335-539; 59746-387; 51552-0559; 0074-3265; 59746-380; 68180-222; 0074-3275; 62175-322; 62331-016; 62704-0027; 33342-187; 59651-020; 72919-420; 47335-614; 68180-221; 68180-223; 25441-0095; 0074-3274; 50268-584; 71740-201; 71741-020; 71741-047; 51407-268; 59746-381; 47335-613; 62175-320; 33342-189; 51407-267; 59651-019; 63629-7193; 65162-321; 65162-323
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H4NO2-
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Acanthosis nigricans23.01.04.001; 16.32.01.003--Not Available
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Arrhythmia02.03.02.001--Not Available
Arterial thrombosis24.01.01.002--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Blood glucose increased13.02.02.002--Not Available
Blood insulin increased13.10.02.001--Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Breast pain21.05.05.003--
Bronchitis22.07.01.001; 11.01.09.001--
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Bursitis15.04.01.001--Not Available
Chills15.05.03.016; 08.01.09.001--
Cholelithiasis09.03.01.002--Not Available
Cholestasis09.01.01.001--Not Available
Cough22.02.03.001--
Dermatitis23.03.04.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages